The Experts below are selected from a list of 4941 Experts worldwide ranked by ideXlab platform
Dierk Scheinert - One of the best experts on this subject based on the ideXlab platform.
-
drug coated balloon versus standard balloon for Superficial Femoral Artery in stent restenosis the randomized Femoral Artery in stent restenosis fair trial
Circulation, 2015Co-Authors: Hans Krankenberg, Thilo Tubler, Maja Ingwersen, Michael Schluter, Dierk Scheinert, Erwin Blessing, Sebastian Sixt, Arne Kieback, Ulrich Beschorner, Thomas ZellerAbstract:Background—Drug-coated balloon angioplasty (DCBA) was shown to be superior to standard balloon angioplasty (POBA) in terms of restenosis prevention for de novo Superficial Femoral Artery disease. For in-stent restenosis, the benefit of DCBA over POBA remains uncertain. Methods and Results—One hundred nineteen patients with Superficial Femoral Artery in-stent restenosis and chronic limb ischemia were recruited over 34 months at 5 German clinical sites and prospectively randomized to either DCBA (n=62) or POBA (n=57). Mean lesion length was 82.2±68.4 mm. Thirty-four (28.6%) lesions were totally occluded; 30 (25.2%) were moderately or heavily calcified. Clinical and duplex ultrasound follow-up was conducted at 6 and 12 months. The primary end point of recurrent in-stent restenosis assessed by ultrasound at 6 months was 15.4% (8 of 52) in the DCBA and 44.7% (21 of 47) in the POBA group (P=0.002). Freedom from target lesion revascularization was 96.4% versus 81.0% (P=0.0117) at 6 months and 90.8% versus 52.6% ...
-
superiority of stent grafts for in stent restenosis in the Superficial Femoral Artery twelve month results from a multicenter randomized trial
Journal of Endovascular Therapy, 2015Co-Authors: Marc Bosiers, Dierk Scheinert, Joren Callaert, Herman Schroe, Koen Deloose, J Verbist, Jeroen M H Hendriks, Patrick Lauwers, Wouter Lansink, Andrej SchmidtAbstract:Purpose: To evaluate the short- and midterm outcomes of the Viabahn endoprosthesis with Propaten Bioactive Surface vs. standard balloon angioplasty for treatment of in-stent restenosis in the Superficial Femoral Artery. Methods: Between June 2010 and February 2012, 83 patients with Superficial Femoral Artery in-stent and Rutherford category 2 to 5 ischemia were enrolled at 7 sites participating in this prospective randomized controlled study (RELINE; ClinicalTrials.gov; identifier NCT01108861). The patients were randomized to treatment with either the heparin-bonded Viabahn endoprosthesis (n=39: 29 men; mean age 67.7±9.8 years) or a standard angioplasty balloon (n=44: 32 men; mean age 69.0±9.7 years). The primary effectiveness outcome was primary patency at 12 months, defined as no restenosis/occlusion within the target lesion based on duplex ultrasound and no target lesion revascularization. The primary safety endpoint was the incidence of serious device-related adverse events within 30 days of the proce...
-
nitinol stent implantation in the Superficial Femoral Artery and proximal popliteal Artery twelve month results from the complete se multicenter trial
Journal of Endovascular Therapy, 2014Co-Authors: John R Laird, Dierk Scheinert, Thomas Zeller, Ash Jain, Robert L Feldman, Jeffrey J Popma, Ehrin J Armstrong, Michael R. JaffAbstract:PurposeTo determine the safety and efficacy of a new-generation nitinol stent with enhanced flexibility in arterial lesions in the Superficial Femoral Artery (SFA) and proximal popliteal Artery (PP...
-
nitinol stent implantation versus balloon angioplasty for lesions in the Superficial Femoral Artery and proximal popliteal Arteryclinical perspective
Circulation-cardiovascular Interventions, 2010Co-Authors: John R Laird, Johannes Lammer, Gary M Ansel, Dierk Scheinert, Alexandra J. Lansky, Barry T Katzen, Maurice Buchbinder, Rajesh Dave, Jeffrey P Carpenter, Ecaterina CristeaAbstract:Background— Controversy still exists regarding the best endovascular treatment strategy for patients with symptomatic disease of the Superficial Femoral Artery. There are conflicting data regarding the benefits of Superficial Femoral Artery stenting and the role of primary stenting compared with balloon angioplasty with provisional stent implantation. Methods and Results— A total of 206 patients from 24 centers in the United States and Europe with obstructive lesions of the Superficial Femoral Artery and proximal popliteal Artery and intermittent claudication were randomized to implantation of nitinol stents or percutaneous transluminal angioplasty. The mean total lesion length was 71 mm for the stent group and 64 mm for the angioplasty group. Acute lesion success (<30%residual stenosis) was superior for the stent group compared with the angioplasty group (95.8% versus 83.9%; P <0.01). Twenty-nine (40.3%) patients in the angioplasty group underwent bailout stenting because of a suboptimal angiographic result or flow-limiting dissection. Bailout stenting was treated as a target lesion revascularization and loss of primary patency in the final analysis. At 12 months, freedom from target lesion revascularization was 87.3% for the stent group compared with 45.1% for the angioplasty group ( P <0.0001). Duplex ultrasound-derived primary patency at 12 months was better for the stent group (81.3% versus 36.7%; P <0.0001). Through 12 months, fractures occurred in 3.1% of stents implanted. No stent fractures resulted in loss of patency or target lesion revascularization. Conclusions— In this multicenter trial, primary implantation of a self-expanding nitinol stent for moderate-length lesions in the Superficial Femoral Artery and proximal popliteal Artery was associated with better acute angiographic results and improved patency compared with balloon angioplasty alone. Clinical Trial Registration— URL: . Unique identifier: [NCT00673985][1]. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00673985&atom=%2Fcirccvint%2F3%2F3%2F267.atom
-
nitinol stent implantation versus balloon angioplasty for lesions in the Superficial Femoral Artery and proximal popliteal Artery twelve month results from the resilient randomized trial
Circulation-cardiovascular Interventions, 2010Co-Authors: John R Laird, Johannes Lammer, Gary M Ansel, Dierk Scheinert, Alexandra J. Lansky, Barry T Katzen, Jeffrey S Carpenter, Maurice Buchbinder, Rajesh Dave, Ecaterina CristeaAbstract:Background—Controversy still exists regarding the best endovascular treatment strategy for patients with symptomatic disease of the Superficial Femoral Artery. There are conflicting data regarding the benefits of Superficial Femoral Artery stenting and the role of primary stenting compared with balloon angioplasty with provisional stent implantation. Methods and Results—A total of 206 patients from 24 centers in the United States and Europe with obstructive lesions of the Superficial Femoral Artery and proximal popliteal Artery and intermittent claudication were randomized to implantation of nitinol stents or percutaneous transluminal angioplasty. The mean total lesion length was 71 mm for the stent group and 64 mm for the angioplasty group. Acute lesion success (<30%residual stenosis) was superior for the stent group compared with the angioplasty group (95.8% versus 83.9%; P<0.01). Twenty-nine (40.3%) patients in the angioplasty group underwent bailout stenting because of a suboptimal angiographic result...
Ecaterina Cristea - One of the best experts on this subject based on the ideXlab platform.
-
nitinol stent implantation versus balloon angioplasty for lesions in the Superficial Femoral Artery and proximal popliteal Arteryclinical perspective
Circulation-cardiovascular Interventions, 2010Co-Authors: John R Laird, Johannes Lammer, Gary M Ansel, Dierk Scheinert, Alexandra J. Lansky, Barry T Katzen, Maurice Buchbinder, Rajesh Dave, Jeffrey P Carpenter, Ecaterina CristeaAbstract:Background— Controversy still exists regarding the best endovascular treatment strategy for patients with symptomatic disease of the Superficial Femoral Artery. There are conflicting data regarding the benefits of Superficial Femoral Artery stenting and the role of primary stenting compared with balloon angioplasty with provisional stent implantation. Methods and Results— A total of 206 patients from 24 centers in the United States and Europe with obstructive lesions of the Superficial Femoral Artery and proximal popliteal Artery and intermittent claudication were randomized to implantation of nitinol stents or percutaneous transluminal angioplasty. The mean total lesion length was 71 mm for the stent group and 64 mm for the angioplasty group. Acute lesion success (<30%residual stenosis) was superior for the stent group compared with the angioplasty group (95.8% versus 83.9%; P <0.01). Twenty-nine (40.3%) patients in the angioplasty group underwent bailout stenting because of a suboptimal angiographic result or flow-limiting dissection. Bailout stenting was treated as a target lesion revascularization and loss of primary patency in the final analysis. At 12 months, freedom from target lesion revascularization was 87.3% for the stent group compared with 45.1% for the angioplasty group ( P <0.0001). Duplex ultrasound-derived primary patency at 12 months was better for the stent group (81.3% versus 36.7%; P <0.0001). Through 12 months, fractures occurred in 3.1% of stents implanted. No stent fractures resulted in loss of patency or target lesion revascularization. Conclusions— In this multicenter trial, primary implantation of a self-expanding nitinol stent for moderate-length lesions in the Superficial Femoral Artery and proximal popliteal Artery was associated with better acute angiographic results and improved patency compared with balloon angioplasty alone. Clinical Trial Registration— URL: . Unique identifier: [NCT00673985][1]. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00673985&atom=%2Fcirccvint%2F3%2F3%2F267.atom
-
nitinol stent implantation versus balloon angioplasty for lesions in the Superficial Femoral Artery and proximal popliteal Artery twelve month results from the resilient randomized trial
Circulation-cardiovascular Interventions, 2010Co-Authors: John R Laird, Johannes Lammer, Gary M Ansel, Dierk Scheinert, Alexandra J. Lansky, Barry T Katzen, Jeffrey S Carpenter, Maurice Buchbinder, Rajesh Dave, Ecaterina CristeaAbstract:Background—Controversy still exists regarding the best endovascular treatment strategy for patients with symptomatic disease of the Superficial Femoral Artery. There are conflicting data regarding the benefits of Superficial Femoral Artery stenting and the role of primary stenting compared with balloon angioplasty with provisional stent implantation. Methods and Results—A total of 206 patients from 24 centers in the United States and Europe with obstructive lesions of the Superficial Femoral Artery and proximal popliteal Artery and intermittent claudication were randomized to implantation of nitinol stents or percutaneous transluminal angioplasty. The mean total lesion length was 71 mm for the stent group and 64 mm for the angioplasty group. Acute lesion success (<30%residual stenosis) was superior for the stent group compared with the angioplasty group (95.8% versus 83.9%; P<0.01). Twenty-nine (40.3%) patients in the angioplasty group underwent bailout stenting because of a suboptimal angiographic result...
-
nitinol stent implantation versus balloon angioplasty for lesions in the Superficial Femoral Artery and proximal popliteal Artery twelve month results from the resilient randomized trial
Circulation-cardiovascular Interventions, 2010Co-Authors: John R Laird, Johannes Lammer, Gary M Ansel, Dierk Scheinert, Barry T Katzen, Jeffrey S Carpenter, Maurice Buchbinder, Rajesh Dave, Ecaterina CristeaAbstract:Background Controversy still exists regarding the best endovascular treatment strategy for patients with symptomatic disease of the Superficial Femoral Artery. There are conflicting data regarding the benefits of Superficial Femoral Artery stenting and the role of primary stenting compared with balloon angioplasty with provisional stent implantation. Methods and results A total of 206 patients from 24 centers in the United States and Europe with obstructive lesions of the Superficial Femoral Artery and proximal popliteal Artery and intermittent claudication were randomized to implantation of nitinol stents or percutaneous transluminal angioplasty. The mean total lesion length was 71 mm for the stent group and 64 mm for the angioplasty group. Acute lesion success ( Conclusions In this multicenter trial, primary implantation of a self-expanding nitinol stent for moderate-length lesions in the Superficial Femoral Artery and proximal popliteal Artery was associated with better acute angiographic results and improved patency compared with balloon angioplasty alone. Clinical trial registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00673985.
-
nitinol stent implantation versus balloon angioplasty for lesions in the Superficial Femoral Artery and proximal popliteal Artery twelve month results from the resilient randomized trial
Circulation-cardiovascular Interventions, 2010Co-Authors: John R Laird, Johannes Lammer, Gary M Ansel, Dierk Scheinert, Alexandra J. Lansky, Barry T Katzen, Jeffrey S Carpenter, Maurice Buchbinder, Rajesh Dave, Ecaterina CristeaAbstract:BACKGROUND: Controversy still exists regarding the best endovascular treatment strategy for patients with symptomatic disease of the Superficial Femoral Artery. There are conflicting data regarding the benefits of Superficial Femoral Artery stenting and the role of primary stenting compared with balloon angioplasty with provisional stent implantation. METHODS AND RESULTS: A total of 206 patients from 24 centers in the United States and Europe with obstructive lesions of the Superficial Femoral Artery and proximal popliteal Artery and intermittent claudication were randomized to implantation of nitinol stents or percutaneous transluminal angioplasty. The mean total lesion length was 71 mm for the stent group and 64 mm for the angioplasty group. Acute lesion success (<30%residual stenosis) was superior for the stent group compared with the angioplasty group (95.8% versus 83.9%; P<0.01). Twenty-nine (40.3%) patients in the angioplasty group underwent bailout stenting because of a suboptimal angiographic result or flow-limiting dissection. Bailout stenting was treated as a target lesion revascularization and loss of primary patency in the final analysis. At 12 months, freedom from target lesion revascularization was 87.3% for the stent group compared with 45.1% for the angioplasty group (P<0.0001). Duplex ultrasound-derived primary patency at 12 months was better for the stent group (81.3% versus 36.7%; P<0.0001). Through 12 months, fractures occurred in 3.1% of stents implanted. No stent fractures resulted in loss of patency or target lesion revascularization. CONCLUSIONS: In this multicenter trial, primary implantation of a self-expanding nitinol stent for moderate-length lesions in the Superficial Femoral Artery and proximal popliteal Artery was associated with better acute angiographic results and improved patency compared with balloon angioplasty alone. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00673985.
Gary M Ansel - One of the best experts on this subject based on the ideXlab platform.
-
three year results of the vibrant trial of viabahn endoprosthesis versus bare nitinol stent implantation for complex Superficial Femoral Artery occlusive disease
Journal of Vascular Surgery, 2013Co-Authors: Patrick J Geraghty, Mark W. Mewissen, Michael R. Jaff, Gary M AnselAbstract:Objective The predominant mode of bare nitinol stent failure is diffuse in-stent restenosis, and failure rates correlate to the length and complexity of the treated lesion. Addition of an expanded polytetrafluoroethylene lining to a nitinol stent frame, as found in the VIABAHN endoprosthesis, mitigates the ingrowth of intimal hyperplasia. We compared the long-term outcomes of complex Superficial Femoral Artery disease intervention using the VIABAHN endoprosthesis to those obtained with bare nitinol stent implantation. Methods One hundred forty-eight patients with symptomatic complex Superficial Femoral Artery disease (TransAtlantic Inter-Society Consensus I class C and D lesions, accompanied by intermittent claudication or ischemic rest pain) were randomized to endovascular intervention using either bare nitinol stent implantation (76 patients) or nonheparin-bonded VIABAHN endoprosthesis deployment (72 patients). Patency, limb hemodynamics, and quality of life were evaluated at 1, 6, 12, 24, and 36 months following intervention. Results The average treated lesion measured 18 ± 8 cm in length, and 58.8% of lesions displayed segmental or complete occlusion. At 3 years, primary patency rates (defined by peak systolic velocity ratio ≤2.0 and no target lesion revascularization) did not significantly differ between patients treated with the VIABAHN stent graft and those who received a bare nitinol stent (24.2% vs 25.9%; P = .392). Stent fractures were significantly more common in bare nitinol stents (50.0%) than in the VIABAHN endoprostheses (2.6%). Primary-assisted patency rates were higher in those receiving bare nitinol stents than the VIABAHN stent graft (88.8% vs 69.8%; P = .04), although secondary patency rates did not differ between bare nitinol stent and stent graft recipients (89.3% vs 79.5%; P = .304). There were no instances of procedure-related mortality or amputation. The hemodynamic improvement and quality measures improved equally in both groups. Conclusions The long-term outcomes of complex Superficial Femoral Artery disease intervention using the VIABAHN endograft and bare nitinol stents are similar. Although primary patency rates are low in both study arms, excellent primary-assisted and secondary patency rates were achieved, with sustained augmentation of limb perfusion and quality-of-life measures. Patency rates diminish most rapidly in the first year after device implantation.
-
nitinol stent implantation versus balloon angioplasty for lesions in the Superficial Femoral Artery and proximal popliteal Arteryclinical perspective
Circulation-cardiovascular Interventions, 2010Co-Authors: John R Laird, Johannes Lammer, Gary M Ansel, Dierk Scheinert, Alexandra J. Lansky, Barry T Katzen, Maurice Buchbinder, Rajesh Dave, Jeffrey P Carpenter, Ecaterina CristeaAbstract:Background— Controversy still exists regarding the best endovascular treatment strategy for patients with symptomatic disease of the Superficial Femoral Artery. There are conflicting data regarding the benefits of Superficial Femoral Artery stenting and the role of primary stenting compared with balloon angioplasty with provisional stent implantation. Methods and Results— A total of 206 patients from 24 centers in the United States and Europe with obstructive lesions of the Superficial Femoral Artery and proximal popliteal Artery and intermittent claudication were randomized to implantation of nitinol stents or percutaneous transluminal angioplasty. The mean total lesion length was 71 mm for the stent group and 64 mm for the angioplasty group. Acute lesion success (<30%residual stenosis) was superior for the stent group compared with the angioplasty group (95.8% versus 83.9%; P <0.01). Twenty-nine (40.3%) patients in the angioplasty group underwent bailout stenting because of a suboptimal angiographic result or flow-limiting dissection. Bailout stenting was treated as a target lesion revascularization and loss of primary patency in the final analysis. At 12 months, freedom from target lesion revascularization was 87.3% for the stent group compared with 45.1% for the angioplasty group ( P <0.0001). Duplex ultrasound-derived primary patency at 12 months was better for the stent group (81.3% versus 36.7%; P <0.0001). Through 12 months, fractures occurred in 3.1% of stents implanted. No stent fractures resulted in loss of patency or target lesion revascularization. Conclusions— In this multicenter trial, primary implantation of a self-expanding nitinol stent for moderate-length lesions in the Superficial Femoral Artery and proximal popliteal Artery was associated with better acute angiographic results and improved patency compared with balloon angioplasty alone. Clinical Trial Registration— URL: . Unique identifier: [NCT00673985][1]. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00673985&atom=%2Fcirccvint%2F3%2F3%2F267.atom
-
nitinol stent implantation versus balloon angioplasty for lesions in the Superficial Femoral Artery and proximal popliteal Artery twelve month results from the resilient randomized trial
Circulation-cardiovascular Interventions, 2010Co-Authors: John R Laird, Johannes Lammer, Gary M Ansel, Dierk Scheinert, Alexandra J. Lansky, Barry T Katzen, Jeffrey S Carpenter, Maurice Buchbinder, Rajesh Dave, Ecaterina CristeaAbstract:Background—Controversy still exists regarding the best endovascular treatment strategy for patients with symptomatic disease of the Superficial Femoral Artery. There are conflicting data regarding the benefits of Superficial Femoral Artery stenting and the role of primary stenting compared with balloon angioplasty with provisional stent implantation. Methods and Results—A total of 206 patients from 24 centers in the United States and Europe with obstructive lesions of the Superficial Femoral Artery and proximal popliteal Artery and intermittent claudication were randomized to implantation of nitinol stents or percutaneous transluminal angioplasty. The mean total lesion length was 71 mm for the stent group and 64 mm for the angioplasty group. Acute lesion success (<30%residual stenosis) was superior for the stent group compared with the angioplasty group (95.8% versus 83.9%; P<0.01). Twenty-nine (40.3%) patients in the angioplasty group underwent bailout stenting because of a suboptimal angiographic result...
-
nitinol stent implantation versus balloon angioplasty for lesions in the Superficial Femoral Artery and proximal popliteal Artery twelve month results from the resilient randomized trial
Circulation-cardiovascular Interventions, 2010Co-Authors: John R Laird, Johannes Lammer, Gary M Ansel, Dierk Scheinert, Barry T Katzen, Jeffrey S Carpenter, Maurice Buchbinder, Rajesh Dave, Ecaterina CristeaAbstract:Background Controversy still exists regarding the best endovascular treatment strategy for patients with symptomatic disease of the Superficial Femoral Artery. There are conflicting data regarding the benefits of Superficial Femoral Artery stenting and the role of primary stenting compared with balloon angioplasty with provisional stent implantation. Methods and results A total of 206 patients from 24 centers in the United States and Europe with obstructive lesions of the Superficial Femoral Artery and proximal popliteal Artery and intermittent claudication were randomized to implantation of nitinol stents or percutaneous transluminal angioplasty. The mean total lesion length was 71 mm for the stent group and 64 mm for the angioplasty group. Acute lesion success ( Conclusions In this multicenter trial, primary implantation of a self-expanding nitinol stent for moderate-length lesions in the Superficial Femoral Artery and proximal popliteal Artery was associated with better acute angiographic results and improved patency compared with balloon angioplasty alone. Clinical trial registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00673985.
-
nitinol stent implantation versus balloon angioplasty for lesions in the Superficial Femoral Artery and proximal popliteal Artery twelve month results from the resilient randomized trial
Circulation-cardiovascular Interventions, 2010Co-Authors: John R Laird, Johannes Lammer, Gary M Ansel, Dierk Scheinert, Alexandra J. Lansky, Barry T Katzen, Jeffrey S Carpenter, Maurice Buchbinder, Rajesh Dave, Ecaterina CristeaAbstract:BACKGROUND: Controversy still exists regarding the best endovascular treatment strategy for patients with symptomatic disease of the Superficial Femoral Artery. There are conflicting data regarding the benefits of Superficial Femoral Artery stenting and the role of primary stenting compared with balloon angioplasty with provisional stent implantation. METHODS AND RESULTS: A total of 206 patients from 24 centers in the United States and Europe with obstructive lesions of the Superficial Femoral Artery and proximal popliteal Artery and intermittent claudication were randomized to implantation of nitinol stents or percutaneous transluminal angioplasty. The mean total lesion length was 71 mm for the stent group and 64 mm for the angioplasty group. Acute lesion success (<30%residual stenosis) was superior for the stent group compared with the angioplasty group (95.8% versus 83.9%; P<0.01). Twenty-nine (40.3%) patients in the angioplasty group underwent bailout stenting because of a suboptimal angiographic result or flow-limiting dissection. Bailout stenting was treated as a target lesion revascularization and loss of primary patency in the final analysis. At 12 months, freedom from target lesion revascularization was 87.3% for the stent group compared with 45.1% for the angioplasty group (P<0.0001). Duplex ultrasound-derived primary patency at 12 months was better for the stent group (81.3% versus 36.7%; P<0.0001). Through 12 months, fractures occurred in 3.1% of stents implanted. No stent fractures resulted in loss of patency or target lesion revascularization. CONCLUSIONS: In this multicenter trial, primary implantation of a self-expanding nitinol stent for moderate-length lesions in the Superficial Femoral Artery and proximal popliteal Artery was associated with better acute angiographic results and improved patency compared with balloon angioplasty alone. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00673985.
John R Laird - One of the best experts on this subject based on the ideXlab platform.
-
nitinol stent implantation in the Superficial Femoral Artery and proximal popliteal Artery twelve month results from the complete se multicenter trial
Journal of Endovascular Therapy, 2014Co-Authors: John R Laird, Dierk Scheinert, Thomas Zeller, Ash Jain, Robert L Feldman, Jeffrey J Popma, Ehrin J Armstrong, Michael R. JaffAbstract:PurposeTo determine the safety and efficacy of a new-generation nitinol stent with enhanced flexibility in arterial lesions in the Superficial Femoral Artery (SFA) and proximal popliteal Artery (PP...
-
nitinol stent implantation versus balloon angioplasty for lesions in the Superficial Femoral Artery and proximal popliteal Arteryclinical perspective
Circulation-cardiovascular Interventions, 2010Co-Authors: John R Laird, Johannes Lammer, Gary M Ansel, Dierk Scheinert, Alexandra J. Lansky, Barry T Katzen, Maurice Buchbinder, Rajesh Dave, Jeffrey P Carpenter, Ecaterina CristeaAbstract:Background— Controversy still exists regarding the best endovascular treatment strategy for patients with symptomatic disease of the Superficial Femoral Artery. There are conflicting data regarding the benefits of Superficial Femoral Artery stenting and the role of primary stenting compared with balloon angioplasty with provisional stent implantation. Methods and Results— A total of 206 patients from 24 centers in the United States and Europe with obstructive lesions of the Superficial Femoral Artery and proximal popliteal Artery and intermittent claudication were randomized to implantation of nitinol stents or percutaneous transluminal angioplasty. The mean total lesion length was 71 mm for the stent group and 64 mm for the angioplasty group. Acute lesion success (<30%residual stenosis) was superior for the stent group compared with the angioplasty group (95.8% versus 83.9%; P <0.01). Twenty-nine (40.3%) patients in the angioplasty group underwent bailout stenting because of a suboptimal angiographic result or flow-limiting dissection. Bailout stenting was treated as a target lesion revascularization and loss of primary patency in the final analysis. At 12 months, freedom from target lesion revascularization was 87.3% for the stent group compared with 45.1% for the angioplasty group ( P <0.0001). Duplex ultrasound-derived primary patency at 12 months was better for the stent group (81.3% versus 36.7%; P <0.0001). Through 12 months, fractures occurred in 3.1% of stents implanted. No stent fractures resulted in loss of patency or target lesion revascularization. Conclusions— In this multicenter trial, primary implantation of a self-expanding nitinol stent for moderate-length lesions in the Superficial Femoral Artery and proximal popliteal Artery was associated with better acute angiographic results and improved patency compared with balloon angioplasty alone. Clinical Trial Registration— URL: . Unique identifier: [NCT00673985][1]. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00673985&atom=%2Fcirccvint%2F3%2F3%2F267.atom
-
nitinol stent implantation versus balloon angioplasty for lesions in the Superficial Femoral Artery and proximal popliteal Artery twelve month results from the resilient randomized trial
Circulation-cardiovascular Interventions, 2010Co-Authors: John R Laird, Johannes Lammer, Gary M Ansel, Dierk Scheinert, Alexandra J. Lansky, Barry T Katzen, Jeffrey S Carpenter, Maurice Buchbinder, Rajesh Dave, Ecaterina CristeaAbstract:Background—Controversy still exists regarding the best endovascular treatment strategy for patients with symptomatic disease of the Superficial Femoral Artery. There are conflicting data regarding the benefits of Superficial Femoral Artery stenting and the role of primary stenting compared with balloon angioplasty with provisional stent implantation. Methods and Results—A total of 206 patients from 24 centers in the United States and Europe with obstructive lesions of the Superficial Femoral Artery and proximal popliteal Artery and intermittent claudication were randomized to implantation of nitinol stents or percutaneous transluminal angioplasty. The mean total lesion length was 71 mm for the stent group and 64 mm for the angioplasty group. Acute lesion success (<30%residual stenosis) was superior for the stent group compared with the angioplasty group (95.8% versus 83.9%; P<0.01). Twenty-nine (40.3%) patients in the angioplasty group underwent bailout stenting because of a suboptimal angiographic result...
-
nitinol stent implantation versus balloon angioplasty for lesions in the Superficial Femoral Artery and proximal popliteal Artery twelve month results from the resilient randomized trial
Circulation-cardiovascular Interventions, 2010Co-Authors: John R Laird, Johannes Lammer, Gary M Ansel, Dierk Scheinert, Barry T Katzen, Jeffrey S Carpenter, Maurice Buchbinder, Rajesh Dave, Ecaterina CristeaAbstract:Background Controversy still exists regarding the best endovascular treatment strategy for patients with symptomatic disease of the Superficial Femoral Artery. There are conflicting data regarding the benefits of Superficial Femoral Artery stenting and the role of primary stenting compared with balloon angioplasty with provisional stent implantation. Methods and results A total of 206 patients from 24 centers in the United States and Europe with obstructive lesions of the Superficial Femoral Artery and proximal popliteal Artery and intermittent claudication were randomized to implantation of nitinol stents or percutaneous transluminal angioplasty. The mean total lesion length was 71 mm for the stent group and 64 mm for the angioplasty group. Acute lesion success ( Conclusions In this multicenter trial, primary implantation of a self-expanding nitinol stent for moderate-length lesions in the Superficial Femoral Artery and proximal popliteal Artery was associated with better acute angiographic results and improved patency compared with balloon angioplasty alone. Clinical trial registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00673985.
-
nitinol stent implantation versus balloon angioplasty for lesions in the Superficial Femoral Artery and proximal popliteal Artery twelve month results from the resilient randomized trial
Circulation-cardiovascular Interventions, 2010Co-Authors: John R Laird, Johannes Lammer, Gary M Ansel, Dierk Scheinert, Alexandra J. Lansky, Barry T Katzen, Jeffrey S Carpenter, Maurice Buchbinder, Rajesh Dave, Ecaterina CristeaAbstract:BACKGROUND: Controversy still exists regarding the best endovascular treatment strategy for patients with symptomatic disease of the Superficial Femoral Artery. There are conflicting data regarding the benefits of Superficial Femoral Artery stenting and the role of primary stenting compared with balloon angioplasty with provisional stent implantation. METHODS AND RESULTS: A total of 206 patients from 24 centers in the United States and Europe with obstructive lesions of the Superficial Femoral Artery and proximal popliteal Artery and intermittent claudication were randomized to implantation of nitinol stents or percutaneous transluminal angioplasty. The mean total lesion length was 71 mm for the stent group and 64 mm for the angioplasty group. Acute lesion success (<30%residual stenosis) was superior for the stent group compared with the angioplasty group (95.8% versus 83.9%; P<0.01). Twenty-nine (40.3%) patients in the angioplasty group underwent bailout stenting because of a suboptimal angiographic result or flow-limiting dissection. Bailout stenting was treated as a target lesion revascularization and loss of primary patency in the final analysis. At 12 months, freedom from target lesion revascularization was 87.3% for the stent group compared with 45.1% for the angioplasty group (P<0.0001). Duplex ultrasound-derived primary patency at 12 months was better for the stent group (81.3% versus 36.7%; P<0.0001). Through 12 months, fractures occurred in 3.1% of stents implanted. No stent fractures resulted in loss of patency or target lesion revascularization. CONCLUSIONS: In this multicenter trial, primary implantation of a self-expanding nitinol stent for moderate-length lesions in the Superficial Femoral Artery and proximal popliteal Artery was associated with better acute angiographic results and improved patency compared with balloon angioplasty alone. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00673985.
Johannes Lammer - One of the best experts on this subject based on the ideXlab platform.
-
nitinol stent implantation versus balloon angioplasty for lesions in the Superficial Femoral Artery and proximal popliteal Arteryclinical perspective
Circulation-cardiovascular Interventions, 2010Co-Authors: John R Laird, Johannes Lammer, Gary M Ansel, Dierk Scheinert, Alexandra J. Lansky, Barry T Katzen, Maurice Buchbinder, Rajesh Dave, Jeffrey P Carpenter, Ecaterina CristeaAbstract:Background— Controversy still exists regarding the best endovascular treatment strategy for patients with symptomatic disease of the Superficial Femoral Artery. There are conflicting data regarding the benefits of Superficial Femoral Artery stenting and the role of primary stenting compared with balloon angioplasty with provisional stent implantation. Methods and Results— A total of 206 patients from 24 centers in the United States and Europe with obstructive lesions of the Superficial Femoral Artery and proximal popliteal Artery and intermittent claudication were randomized to implantation of nitinol stents or percutaneous transluminal angioplasty. The mean total lesion length was 71 mm for the stent group and 64 mm for the angioplasty group. Acute lesion success (<30%residual stenosis) was superior for the stent group compared with the angioplasty group (95.8% versus 83.9%; P <0.01). Twenty-nine (40.3%) patients in the angioplasty group underwent bailout stenting because of a suboptimal angiographic result or flow-limiting dissection. Bailout stenting was treated as a target lesion revascularization and loss of primary patency in the final analysis. At 12 months, freedom from target lesion revascularization was 87.3% for the stent group compared with 45.1% for the angioplasty group ( P <0.0001). Duplex ultrasound-derived primary patency at 12 months was better for the stent group (81.3% versus 36.7%; P <0.0001). Through 12 months, fractures occurred in 3.1% of stents implanted. No stent fractures resulted in loss of patency or target lesion revascularization. Conclusions— In this multicenter trial, primary implantation of a self-expanding nitinol stent for moderate-length lesions in the Superficial Femoral Artery and proximal popliteal Artery was associated with better acute angiographic results and improved patency compared with balloon angioplasty alone. Clinical Trial Registration— URL: . Unique identifier: [NCT00673985][1]. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00673985&atom=%2Fcirccvint%2F3%2F3%2F267.atom
-
nitinol stent implantation versus balloon angioplasty for lesions in the Superficial Femoral Artery and proximal popliteal Artery twelve month results from the resilient randomized trial
Circulation-cardiovascular Interventions, 2010Co-Authors: John R Laird, Johannes Lammer, Gary M Ansel, Dierk Scheinert, Alexandra J. Lansky, Barry T Katzen, Jeffrey S Carpenter, Maurice Buchbinder, Rajesh Dave, Ecaterina CristeaAbstract:Background—Controversy still exists regarding the best endovascular treatment strategy for patients with symptomatic disease of the Superficial Femoral Artery. There are conflicting data regarding the benefits of Superficial Femoral Artery stenting and the role of primary stenting compared with balloon angioplasty with provisional stent implantation. Methods and Results—A total of 206 patients from 24 centers in the United States and Europe with obstructive lesions of the Superficial Femoral Artery and proximal popliteal Artery and intermittent claudication were randomized to implantation of nitinol stents or percutaneous transluminal angioplasty. The mean total lesion length was 71 mm for the stent group and 64 mm for the angioplasty group. Acute lesion success (<30%residual stenosis) was superior for the stent group compared with the angioplasty group (95.8% versus 83.9%; P<0.01). Twenty-nine (40.3%) patients in the angioplasty group underwent bailout stenting because of a suboptimal angiographic result...
-
nitinol stent implantation versus balloon angioplasty for lesions in the Superficial Femoral Artery and proximal popliteal Artery twelve month results from the resilient randomized trial
Circulation-cardiovascular Interventions, 2010Co-Authors: John R Laird, Johannes Lammer, Gary M Ansel, Dierk Scheinert, Barry T Katzen, Jeffrey S Carpenter, Maurice Buchbinder, Rajesh Dave, Ecaterina CristeaAbstract:Background Controversy still exists regarding the best endovascular treatment strategy for patients with symptomatic disease of the Superficial Femoral Artery. There are conflicting data regarding the benefits of Superficial Femoral Artery stenting and the role of primary stenting compared with balloon angioplasty with provisional stent implantation. Methods and results A total of 206 patients from 24 centers in the United States and Europe with obstructive lesions of the Superficial Femoral Artery and proximal popliteal Artery and intermittent claudication were randomized to implantation of nitinol stents or percutaneous transluminal angioplasty. The mean total lesion length was 71 mm for the stent group and 64 mm for the angioplasty group. Acute lesion success ( Conclusions In this multicenter trial, primary implantation of a self-expanding nitinol stent for moderate-length lesions in the Superficial Femoral Artery and proximal popliteal Artery was associated with better acute angiographic results and improved patency compared with balloon angioplasty alone. Clinical trial registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00673985.
-
nitinol stent implantation versus balloon angioplasty for lesions in the Superficial Femoral Artery and proximal popliteal Artery twelve month results from the resilient randomized trial
Circulation-cardiovascular Interventions, 2010Co-Authors: John R Laird, Johannes Lammer, Gary M Ansel, Dierk Scheinert, Alexandra J. Lansky, Barry T Katzen, Jeffrey S Carpenter, Maurice Buchbinder, Rajesh Dave, Ecaterina CristeaAbstract:BACKGROUND: Controversy still exists regarding the best endovascular treatment strategy for patients with symptomatic disease of the Superficial Femoral Artery. There are conflicting data regarding the benefits of Superficial Femoral Artery stenting and the role of primary stenting compared with balloon angioplasty with provisional stent implantation. METHODS AND RESULTS: A total of 206 patients from 24 centers in the United States and Europe with obstructive lesions of the Superficial Femoral Artery and proximal popliteal Artery and intermittent claudication were randomized to implantation of nitinol stents or percutaneous transluminal angioplasty. The mean total lesion length was 71 mm for the stent group and 64 mm for the angioplasty group. Acute lesion success (<30%residual stenosis) was superior for the stent group compared with the angioplasty group (95.8% versus 83.9%; P<0.01). Twenty-nine (40.3%) patients in the angioplasty group underwent bailout stenting because of a suboptimal angiographic result or flow-limiting dissection. Bailout stenting was treated as a target lesion revascularization and loss of primary patency in the final analysis. At 12 months, freedom from target lesion revascularization was 87.3% for the stent group compared with 45.1% for the angioplasty group (P<0.0001). Duplex ultrasound-derived primary patency at 12 months was better for the stent group (81.3% versus 36.7%; P<0.0001). Through 12 months, fractures occurred in 3.1% of stents implanted. No stent fractures resulted in loss of patency or target lesion revascularization. CONCLUSIONS: In this multicenter trial, primary implantation of a self-expanding nitinol stent for moderate-length lesions in the Superficial Femoral Artery and proximal popliteal Artery was associated with better acute angiographic results and improved patency compared with balloon angioplasty alone. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00673985.
-
nitinol stent implantation in long Superficial Femoral Artery lesions 12 month results of the durability i study
Journal of Endovascular Therapy, 2009Co-Authors: Marc Bosiers, Johannes Lammer, Kim Daenens, Giovanni Torsello, Hansmartin Gissler, Johannes Ruef, Stefan Mullerhulsbeck, T Jahnke, Patrick Peeters, Herman SchroeAbstract:Purpose:To evaluate the long-term efficacy and integrity of the PROTEGE EverFlex stent in Superficial Femoral Artery (SFA) lesions in symptomatic patients with peripheral Artery disease (PAD).Metho...
